Conventional and Molecular Diagnostic Method for Patients With Suspected UTI
Primary Purpose
Urinary Tract Infections-UTI
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
culture versus Molecular diagnostics
Sponsored by
About this trial
This is an interventional treatment trial for Urinary Tract Infections-UTI
Eligibility Criteria
Inclusion Criteria:
• Age greater than or equal to 18 and less than or equal to 89 years.
- The PI suspects the patient has a complicated or uncomplicated UTI that requires urine testing to confirm diagnosis
- Able to provide at least 8 ml urine total (urine for 2 pathology tests).
- Is willing to complete one follow up surveys and send back to FH.
Exclusion Criteria:
• Unable or unwilling to provide written informed consent.
- Unable to read and write English (surveys are not available or validated in any other language than English).
- Currently on any antibiotic for any clinical indication.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
A-Culture and Sensitivity group
B-Diagnosis by Molecular Testing
Arm Description
Diagnosis by Culture and Sensitivity group-Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
Diagnosis by Molecular Testing-Treatment based on the results of the PathoGenius molecular testing - Even Numbers on randomization table
Outcomes
Primary Outcome Measures
To quantify differences in the relative abundance and presence of microbial lineages as determined by culture and sequencing technologies.
comparison of culture and sensitivity results to the molecular results
Secondary Outcome Measures
Time (as measured in hours) to preliminary and final identification of organism(s) and antibiotic sensitivity(s) results
time from collection of sample to diagnostic result delivery
Time from participant reported start of UTI symptoms to resolution.
collect time of reported UTI from Subject
Participant Quality of Life as measured by a UTI specific severity and bothersome of symptoms survey taken at baseline (at clinic visit) and at set time points post urine testing
collect data from Subject as outlined in the Quality of Life Assessment
Overall cost
collect data on the overall cost of Subject treatment
Full Information
NCT ID
NCT02623179
First Posted
December 1, 2015
Last Updated
October 3, 2017
Sponsor
Southwest Regional PCR, LLC
1. Study Identification
Unique Protocol Identification Number
NCT02623179
Brief Title
Conventional and Molecular Diagnostic Method for Patients With Suspected UTI
Official Title
Conventional and Molecular Diagnostic Method for Patients With Suspected Urinary Tract Infections: Clinical, Economic, and Quality of Life Outcomes
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
January 15, 2016 (Actual)
Primary Completion Date
December 31, 2016 (Actual)
Study Completion Date
December 31, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Southwest Regional PCR, LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this protocol, the investigators are examining the use of a novel pathogen testing technology and method of identification of antibiotic susceptibility against the conventional C & S testing for patients with both complicated and uncomplicated UTIs. The investigators will examine the two modes in terms of objective patient related outcomes, i.e. 1) diagnostic accuracy and degree of detail of final analysis; 2) time to resolution of symptoms; 3) quality of life as defined by particularly symptomology and "bothersomeness" of the symptoms; and 4) overall cost.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Tract Infections-UTI
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A-Culture and Sensitivity group
Arm Type
Active Comparator
Arm Description
Diagnosis by Culture and Sensitivity group-Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
Arm Title
B-Diagnosis by Molecular Testing
Arm Type
Active Comparator
Arm Description
Diagnosis by Molecular Testing-Treatment based on the results of the PathoGenius molecular testing - Even Numbers on randomization table
Intervention Type
Other
Intervention Name(s)
culture versus Molecular diagnostics
Intervention Description
Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
Primary Outcome Measure Information:
Title
To quantify differences in the relative abundance and presence of microbial lineages as determined by culture and sequencing technologies.
Description
comparison of culture and sensitivity results to the molecular results
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Time (as measured in hours) to preliminary and final identification of organism(s) and antibiotic sensitivity(s) results
Description
time from collection of sample to diagnostic result delivery
Time Frame
1 year
Title
Time from participant reported start of UTI symptoms to resolution.
Description
collect time of reported UTI from Subject
Time Frame
1 year
Title
Participant Quality of Life as measured by a UTI specific severity and bothersome of symptoms survey taken at baseline (at clinic visit) and at set time points post urine testing
Description
collect data from Subject as outlined in the Quality of Life Assessment
Time Frame
1 year
Title
Overall cost
Description
collect data on the overall cost of Subject treatment
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
• Age greater than or equal to 18 and less than or equal to 89 years.
The PI suspects the patient has a complicated or uncomplicated UTI that requires urine testing to confirm diagnosis
Able to provide at least 8 ml urine total (urine for 2 pathology tests).
Is willing to complete one follow up surveys and send back to FH.
Exclusion Criteria:
• Unable or unwilling to provide written informed consent.
Unable to read and write English (surveys are not available or validated in any other language than English).
Currently on any antibiotic for any clinical indication.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael McDonald, MD
Organizational Affiliation
Florida Hospital Celebration Health
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Conventional and Molecular Diagnostic Method for Patients With Suspected UTI
We'll reach out to this number within 24 hrs